Research·October 21, 2026 at 2:00 AM EDT·1 source
Lilly’s retatrutide creeps closer to market for sleep apnea
LLY -2.5%
LLY · last 30 trading days-0.8% since the news
News
What happened
- Eli Lilly is preparing retatrutide for an obesity launch next year.
- The company is also developing data in other indications, including sleep apnea, to support potential future use.
Expected obesity launch
next year
Why it matters
Retatrutide’s potential expansion beyond obesity could affect Lilly’s healthcare pipeline and the competitive outlook for sleep-apnea treatments.
What to watch. Data from retatrutide studies in sleep apnea and other indications, followed by regulatory developments.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 19Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- EarlierOct 19EyePoint's Phase 3 failure; Lilly's China drug delivery deal
- EarlierOct 20STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole
- First reported by Endpoints NewsOct 21Lilly’s retatrutide creeps closer to market for sleep apnea
Who is involved
Lilly’s retatrutide creeps closer to market for sleep apneaEli LillyLLYRetatrutide
Company
Sources (1)
- Endpoints NewsOct 21Lilly’s retatrutide creeps closer to market for sleep apnea
Related
- Yesterday · #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
- Oct 19 · Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- Oct 22 · Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
- Oct 22 · Abu Dhabi lures Eli Lilly, Oura, and Whoop in healthcare push
- Oct 20 · STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole
- Oct 19 · EyePoint's Phase 3 failure; Lilly's China drug delivery deal
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.